Submit to Pharmaceutics Review for Pharmaceutics Edit a Special Issue

Journal Menu

Journal Browser

Special Issue "Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".

Deadline for manuscript submissions: closed (30 March 2023) | Viewed by 7895

Share This Special Issue

Special Issue Editors

Dr. Magdalena Kusaczuk

E-Mail Website
Guest Editor

Department of Pharmaceutical Biochemistry, Medical University of Bialystok, 15-222 Bialystok, Poland
Interests: glioblastoma; epigenetics; pharmacology; cancer; cell stress; chaperones

Dr. Monika Naumowicz

E-Mail Website
Co-Guest Editor

Laboratory of Bioelectrochemistry, Department of Physical Chemistry, Faculty of Chemistry, University of Bialystok, K. Ciolkowskiego 1K, 15-245 Bialystok, Poland
Interests: electroanalytical methods; physicochemical and electrochemical properties of lipid membranes; black lipid membranes; liposomes
Special Issues, Collections and Topics in MDPI journals

Dr. Guillermo Velasco

E-Mail Website1 Website2
Co-Guest Editor

Department of Biochemistry and Molecular Biology, School of Biology, Complutense University, and Instituto de Investigaciones Sanitarias San Carlos (IdISSC), 28040 Madrid, Spain
Interests: cannabinoids; glioma; autophagy; tribbles proteins; sphingolipids; cell signaling; anticancer therapies; midkine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Glioblastoma (GBM) is one of the most aggressive forms of cancer, and has a very poor survival rate. Several factors, such as the presence of the blood–brain barrier (which limits the access of drugs to the brain parenchyma), the high molecular and cellular heterogeneity of GBM, the presence within these tumors of a population of cells with stem-like properties, and the difficulties in developing specific targeted therapies, have hindered the development of effective GBM therapies. Remarkably, plasma membrane properties have a high impact on drug–membrane interactions and drug permeability, and therefore should be considered for the design of novel therapeutic approaches against GBM.

Authors are invited to submit original and review articles covering all aspects of emerging pharmacotherapeutic strategies to fight GBM. These include, but are not limited to, pharmaceutical nanotechnology, nanocarriers, immunotherapy, epigenetic modifiers, innovative analytical approaches, and natural-product-based drugs.

Dr. Magdalena Kusaczuk
Dr. Monika Naumowicz
Dr. Guillermo Velasco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

investigational therapies
pharmacological epigenetic modifiers
targeted therapy
nanotechnology
natural products
immunotherapy
resistance to therapy
glioma stem-like cells
electroanalytical methods
liposomes
physicochemical phenomena at the membrane surface

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments

Chiara Alessia De Benedictis

Ann Katrin Sauer

Giovanni Tosi

Maria Angela Vandelli

Barbara Ruozi

and

Andreas Martin Grabrucker

Pharmaceutics 2022, 14(7), 1450; https://doi.org/10.3390/pharmaceutics14071450 - 12 Jul 2022

Cited by 5 | Viewed by 1473

Abstract

Glioblastoma Multiforme (GBM) is a devastating disease with a low survival rate and few efficacious treatment options. The fast growth, late diagnostics, and off-target toxicity of currently used drugs represent major barriers that need to be overcome to provide a viable cure. Nanomedicines (NMeds) offer a way to overcome these pitfalls by protecting and loading drugs, increasing blood half-life, and being targetable with specific ligands on their surface. In this study, the FDA-approved polymer poly (lactic-co-glycolic) acid was used to optimise NMeds that were surface modified with a series of potential GBM-specific ligands. The NMeds were fully characterised for their physical and chemical properties, and then in vitro testing was performed to evaluate cell uptake and GBM cell specificity. While all targeted NMeds showed improved uptake, only those decorated with the-cell surface vimentin antibody M08 showed specificity for GBM over healthy cells. Finally, the most promising targeted NMed candidate was loaded with the well-known chemotherapeutic, paclitaxel, to confirm targeting and therapeutic effects in C6 GBM cells. These results demonstrate the importance of using well-optimised NMeds targeted with novel ligands to advance delivery and pharmaceutical effects against diseased cells while minimising the risk for nearby healthy cells. Full article

(This article belongs to the Special Issue Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives)

► Show Figures

Figure 1

Open AccessArticle

Iodine Nanoparticles (Niodx^™) for Radiotherapy Enhancement of Glioblastoma and Other Cancers: An NCI Nanotechnology Characterization Laboratory Study

James F. Hainfeld

Sharif M. Ridwan

Yaroslav Stanishevskiy

and

Henry M. Smilowitz

Pharmaceutics 2022, 14(3), 508; https://doi.org/10.3390/pharmaceutics14030508 - 25 Feb 2022

Cited by 3 | Viewed by 1609

Abstract

Effective and durable treatment of glioblastoma is an urgent unmet medical need. In this article, we summarize a novel approach of a physical method that enhances the effectiveness of radiotherapy. High atomic number nanoparticles that target brain tumors are intravenously administered. Upon irradiation, the nanoparticles absorb X-rays creating free radicals, increasing the tumor dose several fold. Radiotherapy of mice with orthotopic human gliomas and human triple negative breast cancers growing in the brain showed significant life extensions when the nanoparticles were included. An extensive study of the properties of the iodine-containing nanoparticle (Niodx) by the Nanotechnology Characterization Laboratory, including sterility, physicochemical characterization, in vitro cytotoxicity, in vivo immunological characterization, and in vivo toxicology, is presented. In summary, the iodine nanoparticle Niodx appears safe and effective for translational studies toward human use. Full article

(This article belongs to the Special Issue Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives)

► Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview

Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics

and

Pharmaceutics 2022, 14(2), 456; https://doi.org/10.3390/pharmaceutics14020456 - 21 Feb 2022

Cited by 4 | Viewed by 1824

Abstract

The most common malignant tumor of the brain is glioblastoma multiforme (GBM) in adults. Many patients die shortly after diagnosis, and only 6% of patients survive more than 5 years. Moreover, the current average survival of malignant brain tumors is only about 15 months, and the recurrence rate within 2 years is almost 100%. Brain diseases are complicated to treat. The reason for this is that drugs are challenging to deliver to the brain because there is a blood–brain barrier (BBB) protection mechanism in the brain, which only allows water, oxygen, and blood sugar to enter the brain through blood vessels. Other chemicals cannot enter the brain due to their large size or are considered harmful substances. As a result, the efficacy of drugs for treating brain diseases is only about 30%, which cannot satisfy treatment expectations. Therefore, researchers have designed many types of nanoparticles and nanocomposites to fight against the most common malignant tumors in the brain, and they have been successful in animal experiments. This review will discuss the application of various nanocomposites in diagnosing and treating GBM. The topics include (1) the efficient and long-term tracking of brain images (magnetic resonance imaging, MRI, and near-infrared light (NIR)); (2) breaking through BBB for drug delivery; and (3) natural and chemical drugs equipped with nanomaterials. These multifunctional nanoparticles can overcome current difficulties and achieve progressive GBM treatment and diagnosis results. Full article

(This article belongs to the Special Issue Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives)

► Show Figures

Figure 1

Open AccessReview

Neuroimmunomodulatory Properties of Flavonoids and Derivates: A Potential Action as Adjuvants for the Treatment of Glioblastoma

Ravena Pereira do Nascimento

Balbino Lino dos Santos

Jéssika Alves Oliveira Amparo

Janaina Ribeiro Pereira Soares

Karina Costa da Silva

Monique Reis Santana

Áurea Maria Alves Nunes Almeida

Victor Diógenes Amaral da Silva

Maria de Fátima Dias Costa

Henning Ulrich

Vivaldo Moura-Neto

Giselle Pinto de Faria Lopes

and

Silvia Lima Costa

Pharmaceutics 2022, 14(1), 116; https://doi.org/10.3390/pharmaceutics14010116 - 04 Jan 2022

Cited by 2 | Viewed by 1980

Abstract

Glioblastomas (GBMs) are tumors that have a high ability to migrate, invade and proliferate in the healthy tissue, what greatly impairs their treatment. These characteristics are associated with the complex microenvironment, formed by the perivascular niche, which is also composed of several stromal cells including astrocytes, microglia, fibroblasts, pericytes and endothelial cells, supporting tumor progression. Further microglia and macrophages associated with GBMs infiltrate the tumor. These innate immune cells are meant to participate in tumor surveillance and eradication, but they become compromised by GBM cells and exploited in the process. In this review we discuss the context of the GBM microenvironment together with the actions of flavonoids, which have attracted scientific attention due to their pharmacological properties as possible anti-tumor agents. Flavonoids act on a variety of signaling pathways, counteracting the invasion process. Luteolin and rutin inhibit NFκB activation, reducing IL-6 production. Fisetin promotes tumor apoptosis, while inhibiting ADAM expression, reducing invasion. Naringenin reduces tumor invasion by down-regulating metalloproteinases expression. Apigenin and rutin induce apoptosis in C6 cells increasing TNFα, while decreasing IL-10 production, denoting a shift from the immunosuppressive Th2 to the Th1 profile. Overall, flavonoids should be further exploited for glioma therapy. Full article

(This article belongs to the Special Issue Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (4 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI